Pregnancy labeling bill
Executive Summary
Senate Health Committee drops Sen. Tom Harkin's (D-Iowa) pregnancy labeling bill from schedule after members could not agree on language. S 2328 would have authorized FDA to require research on the use of drugs during pregnancy (1"The Pink Sheet" July 29, p. 11)...
You may also be interested in...
Pediatric Exclusivity Expansion Floated On Hill; Mandatory Study Bill Pending
An additional three months of exclusivity would be awarded for a company's second round of pediatric studies under a proposed amendment to Sen. Hillary Rodham Clinton's (D-N.Y.) bill to codify FDA's mandatory pediatric study rule
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.